CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01%
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CureVac NV
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Accumulated Depreciation
-€37.4m
CAGR 3-Years
6%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Accumulated Depreciation
-€211.8m
CAGR 3-Years
-54%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Accumulated Depreciation
-€22.9m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Accumulated Depreciation
-€8.2m
CAGR 3-Years
-20%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Accumulated Depreciation?
Accumulated Depreciation
-37.4m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Accumulated Depreciation amounts to -37.4m EUR.

What is CureVac NV's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-16%

Over the last year, the Accumulated Depreciation growth was -26%. The average annual Accumulated Depreciation growth rates for CureVac NV have been 6% over the past three years , -16% over the past five years .

Back to Top